DaVita, Inc. (NYSE:DVA)

CAPS Rating: 3 out of 5

The Company is a provider of dialysis services in the United States for patients suffering from chronic kidney failure, also known as end stage renal disease.

Recs

1
Player Avatar andyrivera255 (< 20) Submitted: 4/24/2008 10:14:25 AM : Outperform Start Price: $49.52 DVA Score: +65.45

Incredible Management, finishing the integration of their acquisition of the largest competitor.

Featured Broker Partners


Advertisement